18Respiratory syncytial virus (RSV) infection is the leading cause of severe lower 19 respiratory tract infections (LRTI) in infants worldwide. The immune responses to RSV 20 infection are implicated in RSV pathogenesis but RSV immunopathogenesis in 21 humans remains poorly understood. We previously demonstrated that IFN-λ1 is the 22 principle interferon induced following RSV infection of infants and well-differentiated 23 primary pediatric bronchial epithelial cells (WD-PBECs). Interestingly, RSV F interacts 24 with the TLR4/CD14/MD2 complex to initiate secretion of pro-inflammatory cytokines, 25 while TLR4 stimulation with house dust mite induces IFN-λ1 production. However, the 26 role of TLR4 in RSV infection and concomitant IFN-λ1 induction remains unclear. 27 Using our RSV/WD-PBEC infection model, we found that CLI-095 inhibition of TLR4 28 resulted in significantly reduced viral growth kinetics, and secretion of IFN-λ1 and pro-29 inflammatory chemokines. To elucidate specific TLR4 signalling intermediates 30 implicated in virus replication and innate immune responses we selected 4 inhibitors, 31 including LY294002, U0126, SB203580 and JSH-23. SB203580, a p38 MAPK 32 inhibitor, reduced both viral growth kinetics and IFN-λ1 secretion, while JSH-23, an 33 NF-κB inhibitor, reduced IFN-λ1 secretion without affecting virus growth kinetics. Our 34 data indicate that TLR4 plays a role in RSV entry and/or replication and IFN-λ1 35 induction following RSV infection is mediated, in part, by TLR4 signalling through NF-36 κB and/or p38 MAPK. Therefore, targeting TLR4 or downstream effector proteins 37 could present novel treatment strategies against RSV. 38 Importance 39 The role of TLR4 in RSV infection and IFN-λ1 induction is controversial. Using our 40 WD-PBEC model, which replicates many hallmarks of RSV infection in vivo, we 41 demonstrated that the TLR4 pathway is involved in both RSV infection and/or 42 3 replication and the concomitant induction of IFN-λ1 and other pro-inflammatory 43 cytokines. Increasing our understanding of the role of TLR4 in RSV 44 immunopathogenesis may lead to the development of novel RSV therapeutics. 45 46